SUMMARY -Acute kidney injury (AKI) is a serious complication associated with increased morbidity and mortality. Total incidence of AKI in hospitalized patients is 1%-5%. As many as 30% of these patients develop AKI in the perioperative period, which is associated with anesthesia and surgery. Despite scientifi c advances and improved surgery techniques, as well as treatment in intensive care units, no signifi cant decrease in AKI incidence has been achieved. To change this outcome, it is important to identify patients at risk of AKI and prevent its occurrence. Correct selection of anesthetic drugs during general anesthesia, adjusted to the individual needs of patients, also infl uences the overall outcome of treatment. Nowadays, inhalational anesthetics are not considered nephrotoxic. Th e more so, inhalational anesthetics have a strong and direct protective eff ect on many organs through preconditioning and postconditioning. New studies have shown that sevofl urane diminishes ischemia/ reperfusion kidney injury and has an anti-infl ammatory eff ect, thus having the potential to reduce the occurrence of AKI. Given the incidence of AKI in the perioperative period, as well as new fi ndings about anesthetics, the issue of anesthetic selection during general anesthesia might be of crucial importance for the fi nal outcome of treatment.
Introduction
Th e choice of general anesthesia best suited to the individual patient needs is of great importance, as the correct selection of anesthesia-inducing drugs can prevent unwanted eff ects on risk-group patients. In addition, it increases the eff ectiveness of the protective effects of individual anesthetics that have been proven in clinical practice, thus improving the outcome of treatment.
Acute kidney injury (AKI) in the perioperative period is characterized by acute kidney function reduction within 48 hours of surgery. In most cases, the damage is partially reversible, and recovery is expected within several weeks. Unfortunately, function recovery is complete only in 15% of patients. AKI is a serious perioperative period complication accompanied by increased mortality, morbidity and treatment costs. It is accompanied by the development and progression of chronic kidney disease, as well as an increased need for future dialysis, particularly in patients already suff ering from disturbances in kidney function.
Th ere are several classifi cations of AKI, previously known as acute renal failure, of which the most widely used are the Kidney Disease Improving Global Outcomes (KDIGO) and Risk, Injury, Failure and Endstage renal disease (RIFLE) classifi cations. Th e main characteristic of AKI is lost kidney function, which can be assessed by measuring serum creatinine levels as a measure of glomerular fi ltration rates, and by measuring urine output volume 1 .
An increase in creatinine occurs only after a decrease in the glomerular fi ltration rate by more than 50%. Th erefore, it is not surprising that even a small serum creatinine increase is associated with increased short-term and long-term mortality, regardless of whether at the time of discharge from the hospital kidney function has partially or fully recovered. Consequently, even a minor creatinine increase needs to be considered seriously, as it represents signifi cant kidney function damage [2] [3] [4] [5] [6] [7] . Th e incidence of AKI in surgery patients depends on the type of surgery. Some types of surgery associated with a high incidence of AKI development are cardiac surgery, abdominal and thoracoabdominal aneurysm surgery, and liver transplantation, while the incidence is signifi cantly lower in general surgery. Despite new fi ndings on AKI and improvements in surgery techniques and treatment in intensive care units, there has been no signifi cant impact on this outcome. Th erefore, identifying the risk groups and prevention of AKI occurrence are of extraordinary importance 8, 9 . Th e results of risk factor studies are often analyzed according to the type of surgery. In a prospective study of patients undergoing major non-cardiac surgery, Kheterpal et al. found an increased risk of developing AKI in seven risk groups: patients older than 59 years, those with a body mass index greater than 32 kg/m 2 , those with chronic obstructive pulmonary disease, liver disease or peripheral vascular occlusive disease, and urgent surgery and high-risk surgery patients 10 . Knowing the preoperative, intraoperative and postoperative risk factors enables the introduction of precautionary measures in each particular perioperative period. Measures are aimed at the prevention of hemodynamic disorders and infl ammatory changes, avoiding nephrotoxic drugs, and the prevention of metabolic disorders. In the preoperative period, optimization of the patient's condition is important. During anesthesia, emphasis is on the choice of anesthetics and on hemodynamic optimization, maintaining medium artery pressure (MAP >65 mm Hg), adequate volume compensation and vasoactive drug administration. In the postoperative period, particularly in intensive care units, where patients are administered a large number of drugs, administration of nephrotoxic drugs should be avoided and drug dosage adapted to kidney function.
Th is review discusses the results of research investigating the use of inhalational anesthetics and their effect on kidney function.
For the time being, modern inhalational anesthetics are basic anesthetic agents, equally used for anesthesia maintenance and for anesthesia induction. Sevofl urane, isofl urane and desfl urane are the most frequently administered inhalational anesthetics. Th e major anesthesiological eff ect of these gases is unconsciousness as a result of the central nervous system depression. In recent years, their non-anesthesiological characteristics, such as their direct eff ect on AKI, have been investigated.
Preconditioning and Postconditioning of Inhalational Anesthetics
It is known that the use of inhalational anesthetics ahead of an expected organ ischemia has a protective eff ect. Th is phenomenon is called anesthetic preconditioning 11, 12 . Inhalational anesthetic agents have a neuroprotective eff ect owing to the activation of adenosine triphosphate (ATP)-dependent potassium channels. Sevofl urane preconditioning for 10 minutes signifi cantly decreases the postoperative release of brain natriuretic peptide, a biochemical marker of myocardial contractile dysfunction. In addition, translocation of protein kinase C isoforms d and e in human myocardium in response to sevofl urane preconditioning has been observed, as well as lower postoperative plasma cystatin C concentrations. Th is indicates better cardiac and renal function in patients.
Th e updated American Heart Association Guidelines recommend administering inhalational anesthetics during general anesthesia in non-cardiac surgery in hemodynamically stable patients at high risk of perioperative myocardial ischemia 13 . Administering inhalational anesthetics after completion of ischemic injury protects several organs, including liver, heart and kidney, which is called anesthetic postconditioning 14, 15 . Th ese facts open up new possibilities for AKI prevention and treatment.
In the past, administering inhalational anesthetics, particularly sevofl urane, was associated with nephrotoxicity as a result of the production of vinyl halide (compound A) during dehydrofl uorination by carbon dioxide absorbers. Compound A has been shown to be nephrotoxic in rats 16 . Contrary to this are the results of the research conducted by Bito et al., who measured the impact of sevofl urane and isofl urane on blood urea nitrogen and serum creatinine concentration values, and on urinary excretion of the kidney-specifi c enzymes. Th e results of the study did not show any signifi cant eff ects of compound A production during sevofl urane anesthesia on kidney function 17 .
Modulation of Ischemia/Reperfusion Injury and Anti-Infl ammatory Eff ects
Th e major cause of AKI incidence is infl ammatory reaction as a consequence of ischemic/reperfusion injury. Infl ammatory response in tubules and endothelium causes breakdown of the endothelial basement membrane and infl ammatory migration into the interstitial space. Th e infl ammatory response can be reduced by activation of regulatory T lymphocytes further facilitating the production of anti-infl ammatory mediators.
Inhalational anesthetics exert powerful multi-organ protective eff ects during the perioperative period and powerfully modulate ischemia/reperfusion injury. It has been proven that they activate multiple pathways to synthesize key cytoprotective and anti-infl ammatory signaling molecules to attenuate ischemic AKI, as has been detailed by Fukazawa and Lee 18 . In ischemia/reperfusion kidney injury, proinfl ammatory cytokines are produced in dying or injured cells of proximal tubules, while the increasing number of chemokines attracting cytotoxic neutrophils and cytotoxic T lymphocytes additionally contributes to the local infl ammatory response.
On the other hand, regulatory T cells produce antiinfl ammatory mediators, including transforming growth factor (TGF)-ß1 and interleukin (IL)-10, and express ectonucleoside triphosphate diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73), which convert proinfl ammatory ATP into cytoprotective adenosine, which produces eff ects via A2a receptors. Th us, regulatory T cells protect the kidney from ischemic/reperfusion injury.
Inhalational anesthetics decrease nuclear translocation of NF-kB, a key proinfl ammatory transcription factor 19 . Furthermore, inhalational anesthetics produce and promote anti-infl ammatory mediators important for renal protection, including TGF-b1 release, CD73 activation, and adenosine generation [20] [21] [22] . Serum creatinine and estimated glomerular fi ltration rate as kidney function markers are insensitive to truly test the effi cacy of the protective role of inhalational anesthetics. Recent research has been aimed at an early predictive marker of AKI, i.e. neutrophil gelatinase associated lipocalin (NGAL). A study of sevofl urane eff ects on renal function in rats after liver transplantation demonstrated signifi cantly reduced NGAL concentrations in the sevofl urane group, as well as smaller epithelial necrosis. In the group anesthetized with sevofl urane, signifi cantly lower serum concentrations of TNF-a, IL-6, and myeloperoxidase were found 2 hours after reperfusion 23 . In parallel with the increase in the number of studies demonstrating the protective role of sevofl urane against the occurrence of AKI, there is also a large number of studies on the protective eff ects of other anesthetics, such as propofol, with regard to AKI. While some studies point to a stronger protective effect of propofol as compared with sevofl urane relative to the occurrence of AKI 24 , others demonstrated that there were no statistically signifi cant diff erences in the incidence of AKI between the two groups 25, 26 .
Conclusion
Acute kidney injury in the perioperative period is a serious complication which often has an adverse eff ect on the course of treatment and outcome in surgical patients. Th is syndrome manifests with increased laboratory values of creatinine without clinical symptoms of anuria. Th e results of studies have shown higher mortality rates even in milder forms of AKI. Th e present-day approach aimed at reducing AKI incidence is based on applying precautionary measures in patients at risk during the perioperative period. AKI needs to be treated in a timely manner in order to ensure maximum kidney function recovery. It is also important to point out the multidisciplinary approach required for such patients, which includes an anesthesiologist, a surgeon, clinical pharmacologist and nephrologist.
Th e major cause of AKI incidence is infl ammatory reaction as a consequence of ischemic/reperfusion injury. Modern inhalational anesthetics, such as sevofl urane and isofl urane, have immunomodulatory renoprotective eff ects based on the activation of regulatory T lymphocytes promoting the production of anti-infl ammatory mediators. Study results confi rm that administering inhalational anesthetics in patients at risk of developing AKI is justifi ed.
Given the above, it is concluded that the selection of the type of anesthetic during general anesthesia remains an important clinical issue, and that further research is needed to clarify the protective eff ect of inhalational anesthetics on the occurrence of AKI.
